WeVote
Log In

Bill

Bill

SCR 87

Relative to focal segmental glomerulosclerosis.

2025-2026 Regular Session Introduced by Catherine Blakespear and 1 co-sponsor

California concurrent resolution recognizes focal segmental glomerulosclerosis as a serious kidney disease, raising awareness and potentially influencing state health policy and research priorities.

Chaptered by Secretary of State. Res. Chapter 139, Statutes of 2025.
#focalsegmentalglomerulosclerosis
0
WeVote Research Nonpartisan
Bill Summary · SCR 87

Legislative bill overview

SCR 87 is a California concurrent resolution that acknowledges focal segmental glomerulosclerosis (FSGS), a rare kidney disease causing progressive kidney function loss. The resolution recognizes the disease, its impact on patients, and likely calls for increased awareness, research support, or resource allocation related to FSGS treatment and patient care.

Why is this important

FSGS affects a small but significant population and can lead to end-stage renal disease requiring dialysis or transplantation, creating substantial medical and financial burdens. Concurrent resolutions like this can elevate public and legislative awareness of rare diseases, potentially influencing funding priorities, research initiatives, and healthcare policy at state and federal levels.

Potential points of contention

  • Limited binding authority: Concurrent resolutions are symbolic rather than legally binding, so the resolution's practical impact depends on voluntary follow-up by agencies and legislators
  • Resource allocation questions: If the resolution implies funding or program commitments without specified appropriations, it may create unfunded expectations
  • Rare disease prioritization: Some may question whether limited state resources should prioritize one rare disease over others with similar or larger patient populations

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.